Renin-Angiotensin System Single Nucleotide Polymorphisms Are Associated with Bladder Cancer Risk.
angiogenesis
angiotensinogen
bladder cancer
renin-angiotensin system
single nucleotide polymorphisms
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
15 11 2021
15 11 2021
Historique:
received:
14
09
2021
revised:
16
10
2021
accepted:
09
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
24
3
2022
Statut:
epublish
Résumé
The renin-angiotensin system (RAS), besides being a major regulator of blood pressure, is also involved in tumor angiogenesis. Emerging evidence suggests a correlation between the use of pharmacologic RAS inhibitors and a delay in urothelial bladder cancer (BC) progression. However, it is unknown whether RAS gene variants may predispose to the development of BC. This study examined the association of RAS single nucleotide polymorphisms (SNPs) including AT1R rs5186, AT2R rs11091046, REN rs12750834, ANG rs4762, and ANG rs699 with the risk of developing non-invasive BC. Peripheral blood samples from 73 patients with T1 urothelial BC (66 men, seven women) and an equal number of healthy subjects (control group) were collected. The TT genotype of the REN rs12750834 SNP (OR: 2.8 [1.3-6.05],
Identifiants
pubmed: 34898568
pii: curroncol28060396
doi: 10.3390/curroncol28060396
pmc: PMC8628720
doi:
Substances chimiques
Angiotensinogen
11002-13-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4702-4708Références
PLoS One. 2014 Mar 21;9(3):e92253
pubmed: 24658029
Clin Genitourin Cancer. 2021 Dec;19(6):540-546
pubmed: 34011489
Pathol Res Pract. 2009;205(12):854-7
pubmed: 19762163
J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):564-71
pubmed: 21490026
Cancers (Basel). 2020 Jun 02;12(6):
pubmed: 32498352
Cancer Treat Res Commun. 2020 Jan 7;23:100165
pubmed: 31982787
Ann Surg Oncol. 2017 Mar;24(3):823-831
pubmed: 27730369
Eur J Clin Invest. 2015 Dec;45(12):1325-32
pubmed: 26509357
Oncol Rep. 2001 Nov-Dec;8(6):1265-7
pubmed: 11605046
J Clin Oncol. 2021 Aug 1;39(22):2486-2496
pubmed: 33989025
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
Int J Hypertens. 2015;2015:930631
pubmed: 26495141
Ann Surg Oncol. 2012 Nov;19(12):3987-93
pubmed: 22872290
Curr Hypertens Rep. 2011 Oct;13(5):356-61
pubmed: 21562941
Cancer Biol Ther. 2015;16(2):307-16
pubmed: 25756513
Nat Rev Cancer. 2005 Sep;5(9):713-25
pubmed: 16110317
Mol Genet Genomic Med. 2019 Oct;7(10):e00788
pubmed: 31407531
Br J Cancer. 2000 Jan;82(1):161-6
pubmed: 10638984
Urol Int. 2018;101(3):269-276
pubmed: 30179882
J Exp Clin Cancer Res. 2017 Jun 9;36(1):77
pubmed: 28599664
Clin Hypertens. 2017 Mar 29;23:12
pubmed: 28361007
J Urol. 2015 Nov;194(5):1214-9
pubmed: 26173101
Cancer Biol Ther. 2010 Feb;9(4):277-85
pubmed: 20026904
Int Urol Nephrol. 2005;37(1):47-53
pubmed: 16132759
BMC Med Genet. 2012 Oct 05;13:94
pubmed: 23036011
PLoS One. 2014 Jul 03;9(7):e101502
pubmed: 24992666
Eur Urol. 2009 Oct;56(4):678-88
pubmed: 18513850
JAMA. 2020 Nov 17;324(19):1980-1991
pubmed: 33201207
Hypertens Res. 2003 Jul;26(7):547-52
pubmed: 12924622